Atrasentan in Treating Patients With Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of hormone-refractory prostate cancer
• Completed protocol ABBOTT-M00-211 or ABBOTT-M00-244 within the past 30 days
• * Disease progression OR
• * Active in trial when double-blind treatment period ended
• PATIENT CHARACTERISTICS:
• Age
• 19 and over
• Performance status
• Karnofsky 60-100%
• Life expectancy
• Not specified
• Hematopoietic
• WBC at least 3,000/mm3
• Absolute neutrophil count greater than 1,000/mm3
• Platelet count at least 100,000/mm3
• Hemoglobin at least 9 g/dL
• Hepatic
• Bilirubin less than 1.5 mg/dL
• AST and ALT no greater than 1.5 times upper limit of normal
• Renal
• Creatinine clearance at least 40 mL/min
• Cardiovascular
• No New York Heart Association class II-IV heart disease
• Pulmonary
• No significant pulmonary disease requiring chronic or pulse steroid therapy within the past 3 months
• Other
• Fertile patients must use 2 effective methods of contraception (1 must be barrier contraception) during and for 8 weeks after study
• No reason that would preclude study
• No significant comorbid condition that would preclude study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• At least 4 weeks since other prior cytotoxic chemotherapy
• No other concurrent cytotoxic chemotherapy
• Endocrine therapy
• Not specified
• Radiotherapy
• At least 4 weeks since prior radionuclides
• No concurrent radionuclides
• Surgery
• Not specified
• Other
• At least 4 weeks since prior investigational agents
• No concurrent antiretroviral therapy for HIV-positive patients
• No concurrent participation in another investigational study